Recommendations for Use of Slow Release Oral Morphine as Opioids Agonist Therapy

Recommendations
by
Cheema, Karan et al via METAPHI

Release Date

2023

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

No

Peer Reviewed

No

Findings/Key points

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT). There is also a plain language summary of the recommendations, intended for patients interested in learning about SROM as OAT.

Keywords

Carries/take-home doses
Clinical guidance
Hospitals
Substitution/OAT
Withdrawal